OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research report released on Thursday morning. The firm issued a sell rating on the stock.

Several other research firms also recently issued reports on OCX. Needham & Company LLC restated a buy rating and set a $4.25 price objective on shares of OncoCyte in a report on Thursday, May 16th. Stephens restated an equal weight rating and set a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Finally, Benchmark restated a speculative buy rating and set a $5.00 price objective on shares of OncoCyte in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $4.06.

OncoCyte Stock Performance

Shares of NASDAQ OCX opened at $3.33 on Thursday. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.70. The firm’s 50-day simple moving average is $2.83 and its 200 day simple moving average is $2.92.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) earnings per share for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. The company had revenue of $0.18 million for the quarter. On average, sell-side analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.